Low Dose Continuous Administration of the Progesterone Receptor Modulator VA2914
Prospective Randomized Multicenter Phase II Study of the Dose-Response Effects of Continuous Administration of Low-Dose VA2914 on Parameters of the Hypothalamic-Pituitary-Gonadal Axis and the Endometrium
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- women in good general health with regular, ovulatory menstrual cycles
- age 18-35
- not pregnant
- not sexually active or reliably use barrier methods of contraception
- normal liver and renal functions and normal laboratory exams
Exclusion Criteria:
- pregnant or breastfeeding
- oral contraception, IUD or other hormonal treatment
- use of agents known to induce hepatic P450
- cardiovascular disorder
- hepatic, renal, or gastrointestinal disorder
- metrorrhagia
- abnormal transvaginal ultrasound (at baseline)
- history of abnormal endometrial biopsy,
- cancer
- depression
- mental illness
- epilepsy
- migraines
- abnormal Pap Smear requiring further exploratory examination
- anovulatory cycle before treatment
- extreme overweight or underweight (body mass index < 16 ou >28)
- subjects unlikely to comply with the protocol, e.g., uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study
- use of narcotics
- more than 10 cigarettes per day, more than 2 glasses of wine/beer per day
- surgical procedures planned in the 6 months following screening visit
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
ovarian hormones
|
|
follicular development
|
|
endometrial histology
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
|---|
|
adverse events
|
|
laboratory parameters
|
|
menstural bleeding patterns
|
|
cervical mucus
|
|
VA2914 concentration
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Philippe Bouchard, MD, Saint Antoine Hospital, Paris, France
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- 2914-002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.